Alta Life Sciences leads €4.2m series-A for Peptomyc

The deal is the first investment for Alta, which led the funding round via Alta Life Sciences Spain I. Other backers included existing investor Healthequity, a Spanish seed investor, and several business angels, which took part in a seed round in 2016.

According to a statement, the company aims to use the fresh capital to boost its product development and validation, and bring it closer to the clinical application. Alta partner Montserrat Vendrell will sit on the company's board.

Alta Life Sciences Spain I is a life-sciences-dedicated venture capital fund that targets seed, early-stage and growth capital investments across several healthcare market segments, including biotechnology, medical devices, diagnostics, genomics and digital health. The fund is managed by Spanish fund-of-funds Altamar Capital Partners, while Alta Life Sciences acts as investment adviser to the fund. The vehicle has a €175m target and a €225m hard-cap, and has raised commitments from several institutional LPs and family offices to date.

Company
Established as a spinout from the Vall d'Hebron Institute of Oncology (VHIO) and of the Catalan Institution for Research and Advanced Studies (ICREA), Peptomyc is based in Barcelona and develops peptide-based therapeutics for cancer treatments. The company employs four people.

People
Alta Life Sciences – Montserrat Vendrell (partner).
Peptomyc – Laura Soucek (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• Southern Europe
• Venture
• Spain